ECONOMIC EVALUATION OF EPIDERMAL GROWTH FACTOR RECEPTOR - TYROSINE KINASE INHIBITOR (EGFR-TKI) DRUGS IN NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT: A SYSTEMATIC REVIEW OF RECENT STUDIES

被引：0
|
作者：
Karim, M. [1 ]
Nabil, A. K. [1 ]
Khodakarami, N. [1 ]
Kum, H. C. [1 ]
Foster, M. J. [1 ]
Ohsfeldt, R. L. [1 ]
机构：
[1] Texas A&M Univ, College Stn, TX USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN133
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [31] Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report
    Lee, Sanghun
    Joo, Jeonghyun
    Kwak, Minah
    Sohn, Kicheul
    Chon, Songha
    ONCOTARGETS AND THERAPY, 2018, 11 : 3943 - 3947
  • [32] CYTOKERATIN 19 FRAGMENT (CYFRA21-1) PREDICTS THE EFFICACY OF THE EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR-TKI) IN NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING EGFR MUTATION
    Tanaka, K.
    Hata, A.
    Kaji, R.
    Fujita, S.
    Takeshita, J.
    Matsumoto, T.
    Monden, K.
    Nagata, K.
    Nanjo, S.
    Otsuka, K.
    Tachikawa, R.
    Otsuka, K.
    Hayashi, M.
    Tomii, K.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2012, 23 : 137 - 138
  • [33] Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer
    Noda, Shoko
    Kanda, Shintaro
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (05) : 547 - 556
  • [34] Mutation in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer (NSCLC)
    Tsai, C
    Chiu, C
    Chou, T
    Li, L
    Chang, K
    Chen, Y
    Tsai, S
    Perng, R
    LUNG CANCER, 2005, 49 : S113 - S113
  • [35] Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR mutations in Singapore
    Chua, B.
    Tan, E. H.
    Lim, D. W-T.
    Ang, M-K.
    Tan, D. S. W.
    Ng, Q-S.
    Kanesvaran, R.
    Jain, A.
    Tan, W-L.
    Toh, C. K.
    Rajasekaran, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [36] Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)
    Gadgeel, Shirish M.
    Ruckdeschel, John C.
    Heath, Elisabeth I.
    Heilbrun, Lance K.
    Venkatramanamoorthy, Raghu
    Wozniak, Antoinette
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (04) : 299 - 305
  • [37] Epidermal growth factor receptor tyrosine kinase inhibitor in treatment of brain metastasis from non-small cell lung cancer
    Zhang, Lan-jun
    Cai, Ling
    Zhu, Jian-fei
    Rong, Tie-hua
    Wu, Shao-xiong
    Chen, Zhong-pin
    Liu, Meng-zhong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] ACTIVATION OF CYTOMEGALOVIRUS IN A PATIENT ON EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR TREATMENT IN NON-SMALL CELL LUNG CANCER
    Dawes, Sean M.
    Plichta, Christine
    Gaddipati, Himaja
    Hamade, Sam
    Biedny, Adam
    de Villate, Oscar F. Parodi Ortiz
    CHEST, 2023, 164 (04) : 972A - 973A
  • [39] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [40] 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC)
    Pao, W
    Miller, VA
    Kris, MG
    SEMINARS IN CANCER BIOLOGY, 2004, 14 (01) : 33 - 40
12345